1[1]Endo A,Kuroda M,Tsujita Y.ML-236A,ML-236B,and ML-236C,new inhibitors of cholesterogenesis produced by penicillium citrinium[J].J Antibiot,1976,29:1346-1348
2[2]Amarenco P,Labreuche J,Lavallee P,et al.Statins in stroke prevention and carotid atherosclerosis:systematic review and up-to-date meta-analysis[J].Stroke,2004,35:2902-2909
3[3]Ridker PM,Cannon CP,Morrow D,et al.C-reactive protein levels and outcomes after statin therapy[J].N Engl J Med,2005,352:20-28
4[4]LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J].N Engl J Med,2005,352:1425-1435
5[5]Amarenco P.Hypercholesterolemia,lipid-lowering agents,and the risk for brain infarction[J].Neurology,2001,57(Suppl 2):S35-S44
6[6]Aikawa M,Rabkin E,Sugiyama S,et al.An HMG-CoA reductase inhibitor,cerivastatin,suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro[J].Circulation,2001,103:276-283
8[8]Nissen SE,Tuzcu EM,Schoenhagen P,et al.Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial[J].JAMA.2004,291:1071-1080
9[9]Plehn JF,Davis BR,Sacks FM,et al.Reduction of stroke incidence after myocardial infarction with pravastatin:the Cholesterol and Recurrent Events (CARE) Study.The Care Investigators.[J].Circulation,1999,99:216-223
10[10]Amarenco P,Bogousslavsky J,Callahan AS,et al.Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL)study[J].Cerebrovasc Dis,2003;16:389-395
